other clinical events between patients with and without severe LV dysfunction at presentation (LVEF ≤ 35%). Mortality observed in patients with TTC was compared with age and sex-specific mortality of the general population using the standardized mortality ratio (SMR) method. The SMR was 3.40 (95% CI, 1.83-6.34) in the TTC population. The only independent predictor of death at Cox analysis was Charlson comorbidity index (hazard ratio, 1.786; P = .0001), but the degree of initial LV dysfunction was not an independent predictor of death.

Conclusions
The recurrence of TTC is rare, but recurrences of chest pain or dyspnea are common in patients with TTC and frequently lead to hospital readmission. Long-term mortality is higher as compared with the control general population and at least in part related to patients' comorbidities. Initial LV dysfunction severity does not seem to impact long-term event rates. Stress-induced or tako-tsubo cardiomyopathy (TTC) is a relatively rare acute cardiac syndrome, largely confined to women and often associated with a stressful event, that may mimic an ST-elevation acute myocardial infarction (STEMI). Chest pain or dyspnea, ischemic electrocardiographic changes, transient left ventricular (LV) dysfunction, and limited release of cardiac injury markers, in the absence of epicardial coronary artery disease (CAD), characterize TTC acute phase. [1] , [2] , [3] , [4] , [5] , [6] In the majority of cases, transient LV dysfunction, which is myocardial-stunning related, involves the LV apical segments and has a full recovery within a few weeks. Direct and indirect catecholamine-induced myocardial injury has been indicated as the main and more likely pathogenetic mechanism. [1] , [2] , [3] , [7] The long-term optimal management and outcome of this cardiac syndrome are unknown. This study sought to evaluate the long-term clinical outcome of patients with TTC.
Abbreviations
Participants
We prospectively enrolled patients admitted to the five hospitals of our urban area who met all four currently accepted diagnostic criteria for TTC: (1) transient hypokinesis, akinesis, or dyskinesis of the LV midsegments with or without apical involvement; the regional wall-motion abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger is often, but not always present; (2) new ECG abnormalities (either ST-segment or T-wave inversion) or modest elevation in cardiac troponin; (3) absence of obstructive CAD or angiographic evidence of thrombosis or plaque rupture; and (4) absence of pheochromocytoma, myocarditis, or hypertrophic cardiomyopathy. [1] The study was approved by the Careggi Hospital Ethics Committee (approval number 0028728), and all patients provided informed consent. The design of this study was a prospective, multicenter, observational registry.
Measurements
All patients were admitted to the cardiac care unit after coronary angiography. Currently recommended treatments for acute coronary syndromes, with therapy directed at relieving myocardial ischemia and preventing thrombotic complications, were provided to patients with TTC. For each patient, the Charlson score index, [8] which represents the most studied and evaluated comorbidity index, was calculated.
The clinical definition of cardiogenic shock was sustained hypotension (systolic BP < 90 mm Hg for at least 30 min) and a reduced cardiac index (< 2.2 L/min/m 2 ) in the presence of elevated pulmonary capillary occlusion pressure (> 15 mm Hg) and tissue hypoxia, including oliguria, clouded sensorium, and cool, mottled extremities.
Outcomes
LV function was evaluated in all patients by two-dimensional echocardiography at admission and at discharge. Following discharge, patients were asked to return to our outpatient clinic for follow-up evaluation at 1 and 6 months, and annually thereafter. All other possible information derived from hospital readmission, or by the referring physician, relatives, or municipality live registries was collected. Primary end points were death, TTC recurrence, and rehospitalization for any cause. Sudden death was defined as an unexpected death that occurs within 1 h after symptom onset, with or without preexisting stable clinical conditions. Cardiovascular death was defined as sudden death or death caused by reinfarction, heart failure, arrhythmia, or fatal vascular disease, including stroke. The cause of death was assigned by the event adjudication committee consensus. At follow-up visit, dyspnea was classified according to the New York Heart Association functional classification system (from class 1 = no limitation of physical activity to class 4 = unable to carry out any physical activity without dyspnea).
Statistical Analysis
Continuous data are expressed as mean ± SD and categorical data as proportions (%). Data were compared by means of the χ 2 test for categorical variables and unpaired t test for continuous variables. Cox proportional hazards multivariate regression analysis was used to identify independent predictors of death among patients with TTC. Hazard ratios (HRs) and 95% CIs were calculated. Furthermore, the multivariate Cox model was used to compare the mortality observed in TTC series (women only) with the mortality observed in women with STEMI admitted to the same hospitals and included in a contemporary prospective registry, [9] adjusting for age and risk factors and the presence of shock at hospital arrival. Finally, mortality observed in patients with TTC and STEMI were compared with age-and sex-specific mortality of the general population of the same area using the standardized mortality ratio (SMR) method. [10] A value of P < .05 was considered significant. Statistical analyses were performed with SPSS 11.5 (SPSS Inc; Chicago, Illinois) and STATA 9 (StataCorp; College Station, Texas).
Baseline Characteristics
From July 2003 to March 2008, among 3,882 patients (1,077 women) hospitalized for acute myocardial infarction, 116 patients with TTC were included in the registry. Among patients with TTC, an emotional or a physical stressful event was detected in 45 (39%) and 34 (29%) patients, respectively. Baseline clinical, ECG, and echocardiographic findings are reported in Table 1 . Urgent angiography showed no significant CAD in patients with TTC. In particular, 92 patients (79%) had truly normal coronary arteries, whereas 24 (21%) had ≤ 50% coronary stenosis. Poor distal run-off was observed in 27 patients (23%), whereas no patient showed coronary calcification or ectatic CAD. Associated comorbidities were detected in 94 patients; of these, COPD was the more frequent (n = 20) (Table 1) . Mean LV ejection fraction (LVEF) at admission was 36% ± 9%. Of the patients with TTC who were discharged alive all except one showed complete LV functional recovery (LVEF > 50%) during follow-up. The only patient who failed to recover a normal LV function had a preexisting hypertensionrelated LV hypertrophy with mild systolic dysfunction. Mean interval time from admission to LV functional recovery was 8 ± 7 days. Calcium channel blockers 10 (9) 8 ( Outcomes Table 2 summarizes in-hospital and long-term clinical outcomes. Two patients died during hospitalization due to refractory heart failure. The first patient who died in-hospital was an 85-year-old woman with a traumatic femoral fracture and COPD who developed chest pain and the classic clinical features of TTC confirmed by angiography. LV dysfunction was severe (LVEF = 30%) and associated with moderate to severe functional mitral regurgitation. This patient developed refractory cardiogenic shock that did not improve with inotropic drugs or balloon pump and the patient died 24 h after TTC diagnosis. The second patient who died in-hospital was an 80-year-old woman with myasthenia gravis who, after TTC presentation, developed cardiac and respiratory failure that did not improve with intubation and inotropic agents, and the patient died 4 days after hospital admission. The other in-hospital complications were nonfatal heart failure, cardiogenic shock, cardiac arrhythmias, LV thrombosis, functional mitral regurgitation, and LV outflow tract obstruction. Long-term follow-up rate was 100%; follow-up length was 2.0 ± 1.3 years. Two-thirds of patients (n = 78) had a survival free from major adverse events; of these, 64 (55%) were truly asymptomatic, whereas 14 (12%) had chest pain episodes. One-third of patients (n = 38) experienced a major adverse event. There were 11 deaths (9%) ( Table 3) . Seven (6%) deaths were classified as cardiovascular: Two patients died during the index hospitalization from refractory heart failure, two patients had fatal ischemic strokes, and three patients had an out-of-hospital sudden death (two of them were on β-blocker therapy). TTC recurrence was excluded in the two patients with fatal ischemic strokes. Four deaths were considered noncardiovascular and were due to COPD (n = 2), pneumonia (n = 1), and sepsis (n = 1). There was no significant difference in mortality (P = .284) or in the other clinical events between patients with an initial LVEF ≤ 35% and those with an LVEF > 35% (after excluding the two patients who died during hospitalization the out-of-hospital mortality rates were 9% and 7%; P = .694). CRI = chronic renal insufficiency; FU = follow-up; HF = heart failure; NA = not applicable; PAD = peripheral artery disease; PAF = parossistic atrial fibrillation; RF = respiratory failure; UNK = unknown. See Table 1 legend for expansion of other abbreviations.
Two patients experienced TTC recurrence during follow-up. The first patient was a 64-year old woman who had the first episode of TTC in June 2005 following confrontation and argument with the neighbors. She completely recovered LV function and was asymptomatic for 3 years with calcium channel blocker therapy. However, in 2008 following a new quarrel with the neighbors she presented again with a classic TTC episode. The second patient with TTC recurrence was a 66-year-old woman smoker with hypertension who developed a TTC episode after a burglary at her home. She recovered completely, but 1 year later she developed a new TTC episode while she was waiting for uterine surgery. Fifteen patients had a rehospitalization that was classified as cardiovascular (chest pain [n = 6], dyspnea [n = 4], heart failure, atrial fibrillation, hypertensive state, and TTC recurrences). There were also 13 cases of noncardiovascular rehospitalization, mainly related to comorbidities. Six patients had hospital admission due to COPD exacerbation. No outcome difference was observed between patients with and without an antecedent stressful event before the index episode. By Cox analysis, the only independent predictor of death was Charlson comorbidity index (HR, 1.786 [95% CI, 1.299-2.456]; P = .0001), but initial LV dysfunction degree was not an independent predictor of death. The SMR in patients with TTC was 3.40 (95% CI, 1.83-6.34). The SMR in patients with STEMI admitted to the same hospitals in the same period and included in a contemporary prospective registry [9] was 5.17 (95% CI, 4.19-6.37). The adjusted HR of TTC cases vs patients with STEMI was 0.48 (95% CI, 0.25-0.94; P = .016).
Effect of β-Blockers Recommendation
There was no significant difference in all the baseline characteristics between patients with (n = 81) and without (n = 35) β-blockers recommended at discharge. A lower but not significant mortality was observed at long-term follow-up in patients with β-blockers recommended at discharge as compared with those without (Table 2) . However, patients with β-blockers showed a trend toward a higher rehospitalization rate, mainly driven by noncardiovascular rehospitalizations (Table 2) . One patient treated with β-blockers experienced TTC recurrence.
Few but important findings related to the natural history of stress-induced cardiomyopathy or TTC emerge from the analysis of the reported data: (1) TTC recurrence is rare, (2) recurrences of chest pain and dyspnea are common in these patients and lead to frequent rehospitalizations, (3) TTC mortality rate is higher than the expected mortality in the general population, and (4) long-term mortality in TTC seems to be not influenced by the initial LV dysfunction severity.
Previous TTC outcome data derived mainly from retrospective studies with small populations and limited periods of observation. In our prospective registry, almost all of the patients admitted to the hospital for TTC (98.3%) were discharged alive and presented complete LV functional recovery within a few days or weeks. TTC recurrence was documented in only two patients (1.7%). This percentage is relatively low as compared with previous reports. [5] , [6] However, recurrence of any type of chest pain (either typical or atypical) and/or dyspnea were frequently presented by patients who suffered TTC and generated challenging differential diagnoses. The ECG and echocardiographic findings and cardiac injury marker evaluations were crucial to detect or rule out the TTC recurrence. As expected by the advanced age of these patients, rehospitalizations were common and mainly related to comorbidities.
The analysis of the SMR revealed that patients with TTC are three times more likely to die when compared with the general population. This finding must be confirmed in larger study populations. However, TTC seems to be associated with a long-term survival rate that is intermediate between the one of the general population and the one of patients with STEMI. [4] Comorbidity (Charlson index) was the only predictor of mortality in the TTC population, and we can speculate that the observed mortality excess may be at least in part related to the associated diseases. After discharge, the incidence of sudden death (2.6%) was not negligible and it merits further consideration. At the present time there are no data available to recommend proper preventive strategies besides an accurate patient follow-up, an aggressive treatment of cardiovascular risk factors, and an optimal management of comorbidities.
Interestingly, the severity of initial LV dysfunction seems not to impact long-term survival, since LV fully recovers in almost all of the patients. However, severe LV dysfunction, especially when associated with functional mitral regurgitation, has been identified as a potent predictor of hazardous clinical manifestations, including pulmonary edema and cardiogenic shock in the TTC acute phase. [11] β-Blocker therapy, which is actually recommended in the majority of TTC given the hypothesis of a catecholamine-induced myocardial injury, seems not to completely prevent the recurrence of TTC; in fact, one patient had a TTC recurrence during β-blocker therapy. Moreover, 63 of the enrolled patients had previous hypertension and 17 of them were taking β-blockers at the time of the index event. Thus, we can conclude that further data are needed to establish the value of β-blocker therapy during long-term follow-up after TTC. On the other hand, the in-hospital use of β-blockers in patients with LV dysfunction and LV outflow tract obstruction is mandatory. [12] 
Study Limitations
Our results must be evaluated in light of some study limitations. First, true TTC natural history should include syndrome recurrence in patients with subclinical presentation as well as in patients with out-of-hospital sudden death. Unfortunately, autopsy data of patients who died suddenly were not available. Second, even if it seems unlikely, we cannot exclude the contribution of atherosclerotic CAD development to the higher mortality rate of TTC as compared with the one of the general population. In fact, endothelial dysfunction, which constitutes the first step of atherosclerosis, has been suggested to be present in TTC. [2] Finally, because of the nonrandomized nature of the study, data on β-blocker therapy are not conclusive and are only hypothesis generating.
The recurrence of TTC is rare, although recurrences of chest pain or dyspnea are common in patients with TTC and lead to frequent rehospitalizations. Long-term mortality is higher as compared with the control general population and at least in part related to patients' comorbidities. Initial LV dysfunction severity seems not to impact long-term event rates.
